Autosomal dominant polycystic kidney disease (ADPKD) is a common, progressive, adult onset disease that is an important cause of end stage renal disease (ESRD), requiring transplantation or dialysis. Mutations to PKD1 or PKD2 (~85% and ~15% of resolved cases, respectively) are the known causes of ADPKD. Extrarenal manifestations include an increased level of intracranial aneurysms (ICA) and polycystic liver disease (PLD), which can be severe and associated with significant morbidity. Autosomal dominant PLD (ADPLD) with no/very few renal cysts is a separate disorder caused by PRKCSH, SEC63 or LRP5 mutations. After screening, 7-10% of ADPKD and ~50% of ADPLD families were genetically unresolved (GUR), suggesting further genetic heterogeneity of both disorders. Whole exome sequencing of six GUR ADPKD families identified one with a missense mutation to GANAB, encoding the glucosidase II, α subunit (GIIα .
Mutations to

INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited disorders, ~1/1000 individuals affected worldwide, that is characterized by progressive kidney cyst development and expansion 1; 2 . In ~50% of cases, ADPKD results in end stage kidney disease (ESRD), with 4-10% of ESRD worldwide due to ADPKD 3 . ADPKD is caused by mutations to PKD1 [MIM: 601313] or PKD2 [MIM: 173910] (~85% and ~15% of mutation resolved families, respectively) [4] [5] [6] [7] . Genotype/phenotype studies indicate an average age at ESRD of 55.6y associated with truncating PKD1 mutations, compared to 67.9y for PKD1 nontruncating and 79.7y for PKD2 [MIM: 613095] 8 . An earlier decline in renal function (measured by estimated glomerular filtration rate; eGFR) and larger kidneys (height adjusted, MRI determined total kidney volume; htTKV) are also associated with PKD1 [MIM: 173900] 6; 9 . The PKD1 and PKD2 proteins, polycystin-1 (PC1) and PC2, respectively, are membrane glycoproteins, with the primary cilium a likely functional site 10 . PC1 is cleaved at the GPS site and this cleavage is essential for function 11; 12 . PC1 consists of two glycoforms of the N-and Cterminal GPS cleaved products -mature, Endoglycosidase H (EndoH) resistant (NTR/CTR) and immature, EndoH sensitive (NTS/CTS) [13] [14] [15] . The level of the mature glycoforms is associated with disease severity, and complexing with PC2 is critical for PC1 maturation and surface/ciliary localization 13; 16; 17 . In a number of comprehensive studies of the genes mutated in ADPKD, 7-10% of families are genetically unresolved (GUR) 6-8; 18 . The typical finding of mild kidney disease in GUR cases 6 , suggests that few such families are explained by missed, fully penetrant mutations at the complex, segmentally duplicated, PKD1 locus 4; 19 . However, hypomorphic mutations at the existing loci, including due to mosaicism 20; 21 , phenocopies associated with autosomal dominant tubulointerstitial kidney disease (ADTKD) loci 22; 23 [29] [30] [31] [32] .
PRKCSH encodes the glucosidase II, β subunit (GIIβ 33; 34 , with GII being an ER-resident enzyme that catalyzes hydrolysis of the middle and innermost glucose residues on peptidebound oligosaccharide and triggers quality control assessment of glycoprotein folding through the calnexin/calreticulin cycle [35] [36] [37] [38] [39] [40] . The SEC63 protein facilitates the translocation of secreted or membrane proteins across the endoplasmic reticulum (ER) membrane [41] [42] [43] [44] .
Induced loss of
Prkcsh or Sec63 in mouse kidneys results in PKD, with an interactive network with PC1 and PC2 proposed, with PC1 as the rate-limiting component 14 . This suggests that PRKCSH mutation may act through PC1 depletion, although PC2 reduction has also been noted with Prkcsh depletion/loss 45; 46 . There is strong evidence of further genetic heterogeneity in ADPLD, with only ~50% of affected individuals explained by the known genes mutated in this disease 28; 47 .
In this study we have employed global and focused screening of GUR ADPKD/ADPLD families to identify a gene mutated in ADPKD/ADPLD. Characterization of cells null for this gene links the pathogenesis to the maturation and localization of PC1 and PC2.
SUBJECTS AND METHODS
Sample and data collection and clinical analysis
The relevant institutional review boards and ethics committees approved all studies, and participants gave informed consent. , and adjusted for height (htTKV or htTLV). Enlarged kidneys or livers were defined as the mean +2SD of normal htTKV or htTLV adjusted for average height 27; 49 . Kidney function was calculated from clinical serum creatinine measurements using the CKD-EPI formula in adults 50 and the Schwarz formula in the pediatric case 51 and expressed as ml/min/1.73m 2 . Age at onset of high blood pressure was defined as when the affected individual started antihypertensive medication.
Whole exome sequencing (WES) and bioinformatics analysis
Families were defined GUR when no mutations were detected from Sanger sequencing and MLPA analysis of the PKD1 and PKD2 genes. In addition, the Genkyst cohort, including families PK20016 and PK20017, and P1174, were screened for HNF1B Table S1 .
Sanger sequencing and mutation validation
Primers to amplify the 25 exons of GANAB (NM_198335.3), plus ~100bp of flanking IVS, were designed using MacVector 12.0.6 and 50ng of genomic DNA was used for PCR amplification (primers and PCR conditions available upon request). Sanger sequencing was performed at
Beckman Coulter Genomics using standard approaches and variants identified with the Mutation Surveyor software (Softgenetics) and designated on the 25 exon GANAB isoform and corresponding protein (NP_938149.2). Segregation analysis was performed where samples were available by sequencing the exonic fragment containing the mutation. Additionally, none of these variants were seen in the NHLBI Exome Sequence Project. Sanger sequencing detected amino acid changes were evaluated with the programs SIFT and Align GVGD and the atypical splicing change in M656 was evaluated with the BDGP Splice Site Prediction by Neural Network site. The origin of the GANAB families is: US, M263, M641, 290100, M656, M472; France, PK20016, PK20017; Macedonia, P1174; and Spain, P1073. One family came from the HALT PKD cohort, two from Genkyst, and the remainder from the Mayo PKD Center population.
Generation of targeted GANAB mutated cell lines using CRISPR/Cas9
Guide RNAs predicted to have the lowest off-targeting effect were cloned into pX330; SpCas9 and single guide RNA containing plasmid and verified by sequencing (see Table S2 for sequences). GANAB ex11-IVS12 was PCR amplified (primer sequences available on request) and the 550bp genomic product cloned into pCAG-EGxxFP 52 using BamHI and EcoRI restriction sites. Each gRNA was then co-transfected with p-CAG-EG-GANAB(11-IVS-12)-FP in RCTE cells and scored after 24hrs for EGFP positive cells. gRNA4 was selected as the most efficient cutter and used to generate cell lines. pX330-gRNA4 was transfected into WT RCTE cells by electroporation and the cells allowed to recover for 36hrs prior to splitting and re-seeding as single cell suspensions in a 96-well plate. Cells were grown for 10 days to establish single clone cell colonies, split two fold and re-seeded for screening. Screening was performed using genomic DNA extraction followed by amplification using GANAB ex11-IVS12 primers followed by the T7 mismatch assay. For this assay, PCR amplicons were denatured at 95°C for 2min
and cooled gradually to 25°C at a rate of -2°C per second. The reaction mixture was then subjected to T7 endonuclease (T7E1, NEB) for 20min at 37°C and visualized in 2% agarose gels. Clones were additionally screened using western blotting for GIIα and Sanger sequencing.
Generating FLAG-GIIα constructs with missense variants
C-terminal Myc-DDK tagged GIIα (isoform 3, NM_198335.3) was obtained from Origene.
Missense mutations were introduced by site-directed mutagenesis using Q5 high-fidelity polymerase (NEB) (primer sequences are shown in Table S3 ).
Western studies, glycosylation analysis and immunoprecipitation
For crude membrane protein purification, cells were grown to confluence, washed with 
Surface glycoprotein labeling and immunoprecipitation
Surface glycoprotein labeling of living cells was performed as previously described 16 . Monolayer cells in 10cm culture dishes were washed twice with ice-cold DPBS then oxidized at 4°C in 1mM analyses. Tris-Acetate gels were washed with ultrapure water and stained using ProteoSilver stain kit according to manufacturer's instructions (Sigma) for silver staining.
Transfection, confocal microscopy, immunofluorescence (IF) and surface PC1 labeling RCTE cells were split 1:2 the day before electroporation and transfected at ~80% confluency.
Electroporation of RCTE cells was performed using the Biorad Gene Pulser with a square wave protocol: 110V, 25ms pulse and 0.2cm cuvettes (Biorad) in electroporation buffer (20mM HEPES, 135mM KCl, 2mM MgCl2, 0.5% Ficoll 400, pH 7.6). TagGFP-PC2 and mCherry-PC1 used in this study were previously described 16 . RCTE cells were grown on glass cover slips, washed once with DPBS, fixed in 3.5% paraformaldehyde (PF) for 30min, permeabilized with 0.1% Triton in DPBS (pH 7.5), washed again in PBS, and incubated in blocking buffer (10% normal goat serum (NGS), 1% BSA, 0.1% Tween in PBS pH 7.5) for 30mins. After three PBS washes, primary antibodies were added in IF buffer (1% BSA, PBS pH 7.5, 0.1% Tween) for 2hrs at room temperature or overnight at 4°C with gentle agitation. After three PBS washes, conjugated secondary antibody (AlexaFluor, Invitrogen) was added for 1hr. DAPI was added for 1 min to stain nuclei.
For surface labeling of mCherry-PC1, transfected RCTE cells were cooled at 4°C for 15min, washed once in ice-cold PBS and pre-chilled mCherry antibody (BioVision), and incubated in 0.5% BSA in PBS for 30mins at 4°C. Cells were then fixed in 3.5% paraformaldehyde (PF) and conjugated secondary antibody added for 30mins in IF buffer. Confocal microscopy was performed using a Zeiss Axiovert equipped with Apotome.
For pH-shift/SDS IF, the fixation/antigen retrieval method was performed to visualize endogenous PC2 in MEFs. Cells were grown to 100% confluency and serum starved for 48hrs, fixed in 3% PF (pH 7.5) for 15min, fixed in 4% (PF pH 11 in 100mM borate buffer) for 15min, and then permeabilized in 5% SDS for 5min, to partially denature the protein. 
RESULTS
Identification of GANAB as a gene mutated in ADPKD by whole exome sequencing
Following PKD1 and PKD2 mutation analysis for base pair and larger rearrangements, we identified 327 GUR families out of ~3600 screened. The origin of the GUR families was the HALT-PKD (64) ADPKD clinical trial, and the CRISP (16), and Genkyst (124) ADPKD observational studies. In addition, GUR families were included from screening ADPKD, and mild renal cystic disease families, including ones with PLD, at the Mayo PKD Center (123).
While a firm clinical diagnosis of ADPKD was made in 247 GUR pedigrees, in 80 pedigrees the disease presentation was more atypical, with cystic kidney disease without kidney enlargement, although the vast majority exceeded the defined ultrasound or MRI criteria for ADPKD diagnosis 54; 55 . In the 7 remaining families, the disease presentation was more consistent with ADPLD, although all but one had some renal cysts. PRKCSH and SEC63 screening was also performed in these families before inclusion. Six multiplex ADPKD-like GUR families were screened by whole exome sequencing (WES) and standard screening methods employed to identify mutated, dominant genes (see Subjects and Methods), with detected genes/variants listed in Table S1 . A missed PKD1 mutation was identified in one family (M560). and Methods), a figure similar to PKD2 (7/37.6; pLI=1.0), and consistent with it being a dominant cause of disease 56; 57 .
The GANAB missense variant, c.1265G>T; p.Arg422Leu, was detected by WES in family M263
and found in the affected father and daughter but not the unaffected daughter ( Figure 1A-C) . In silico analysis, including conservation in a multi-sequence alignment (MSA) of orthologous proteins to yeast and related glucosidases showed and that this variant is highly predicted to be pathogenic ( Figure 1D,E and legend) . Both of the affected individuals had mild kidney and significant liver cystic disease ( Figure 1F ,G and Table 1 ).
Identification of further ADPKD families with GANAB mutations
Given that mutation to GANAB may explain unresolved ADPKD families, we analyzed our remaining GUR cohort of 321 families by Sanger sequencing of the coding region. From this analysis we identified eight additional families with GANAB mutations: three frameshifting, two splicing, one nonsense and two missense mutations (Table 1) . Data from the Exome Aggregation Consortium (ExAC) showed that all the GANAB variants, except c.152_153delGA
(reported once), have not been reported in the 60,706 unrelated individuals sequenced as part of various disease-specific and population genetic studies 56 .
The GANAB frameshifting mutation, c.1914_1915delAG; p.Asp640Glnfs*77, was found in two families, M641 and 290100 (Figure 2A-E, Figures S2A,B , S3A, Table 1 ). In M641, two sisters had relatively mild PKD with variable liver cysts. The family history was unclear with the father dying at 75y with renal cell cancer but no reported cysts, with no information on the mother.
Both sisters had ICA (see Figure 2 legend for details) and the father was reported to have a ruptured aneurysm. In family 290100, the father and son both had mild PKD, with multiple liver cysts in the father but not the son.
In family P1174, the GANAB missense variant, c.1214C>G; p.Thr405Arg, was found in three generations, including III-1 where renal cysts were detected incidentally in infancy ( Figure 2F -H, Figures S2C, S3B , Table 1 ). The substituted residue is invariant in orthologs and conserved in related proteins ( Figure 2I ,J). The GANAB splicing mutation, c.2690+2_+7del, was found in four affected family members in M656 ( Figure 2K ,L, Figures S2D, S3C ,D, Table 1 ). All members had no to mild cystic liver disease and mild kidney disease, apart from II-3 who had multiple kidney cysts. Of note, the mother (without the GANAB mutation) had multiple cysts of unresolved etiology. PK20016 had the splicing mutation c.39-1G>C and PK20017 the nonsense mutation c.2176C>T; p.Arg726*, and both had only one known affected family member ( Figure 3A -D, Figure S2E ,F, Table 1 ). Both cases had multiple kidney cysts and a few liver cysts.
Identification of ADPLD-like families with GANAB mutations
In contrast to the described ADPKD cases, in families P1073 and M472 ADPLD was considered as a possible diagnosis, although a few renal cysts were present. P1073 had the missense mutation, c.2515C>T; p.Arg839Trp, which is at an invariant site in orthologs and segregates in three affected family members ( Figure 3E -G, Figure S2G , Table 1 ). As indicated, there were very few renal cysts but multiple liver cysts, with the daughter, II-1, requiring a liver transplant at 43y. M472, II-1, with the GANAB frameshifting mutation c.152_153delGA; p.Arg51Lysfs*21
( Figure 3H ,I, Figure S2H , Table 1 ), had a few small kidney cysts but severe PLD that required partial liver resections. A similar phenotype with less severe PLD was seen in II-2 ( Figure S3E ), although a sample was unavailable for mutation analysis.
Characterization of the effect of GANAB loss on PC1 and PC2 maturation/localization
From the genetic studies, mutation to GANAB was shown to be a cause of ADPKD/ADPLD, so we next explored the mechanism of pathogenesis by cellular analysis. CRISPR/Cas9 targeting of GANAB ex12 in human renal cortical tubular epithelial (RCTE) cells generated clones with biallelic frameshifting mutations (null; Clone C6) or a single in-frame deletion (heterozygous; E4; Figure S4A-D) . Analysis of the PC complex immunocaptured with PC2 or PC1 CT antibodies in GANAB -/-cells showed that the PC1 N-terminal, mature product (PC1-NTR) was absent ( Figure   4A ,B). In contrast, full length (GPS uncleaved) PC1, PC1-NTS and PC2 were elevated, indicating that GIIα plays a major role in PC1 maturation. We previously showed an interdependence of PC1 and PC2 for localization, including to cilia 16 , and so to assess localization of the polycystin complex PC2 was analyzed. Ciliary localization of PC2 was completely absent in GANAB -/-cells, although cilia formed normally ( Figure 4C , Figure S4E) 16;
17
. Since affected individuals harbored just one GANAB mutation we assayed GANAB +/-cells and found a proportional, ~50%, depletion of PC1-NTR ( Figure 4D,E) . Analysis of the maturation of other membrane proteins (EGFR and E-cadherin) showed they were not, or only minorly, affected by loss of GIIα ( Figure 4A ). Further analysis of terminally glycosylated proteins in GANAB -/-cells did not suggest a global disruption of surface localized proteins ( Figure S4F-H) .
Functional analysis of GANAB mutations/variants
To determine the effect of GANAB loss on PC1 localization by immunofluorescence (IF) and to test the pathogenicity of detected GANAB/GIIα variants, wildtype and GANAB -/-cells were cotransfected with tagged PC1 and PC2 constructs (mCherry-PC1-V5 and GFP-PC2; Figure   5A ,B) 16 . GIIα loss prevented efficient surface localization of tagged PC1, which was restored by co-expression of WT FLAG-GIIα ( Figure 5A ). Identified GIIα missense mutations (p.Thr405Arg, p. Arg422Leu and p.Arg839Trp), expressed as FLAG-GIIα constructs, failed to rescue PC1 surface localization in GANAB -/-cells ( Figure 5A ), whereas three other variants considered likely neutral (c.284A>G; p.Gln95Arg, c.760A>G; p.Thr254Ala and c.991C>T; p.Arg331Cys) restored surface localization ( Figure S5 ).
DISCUSSION
The combination of the human genetic studies and cellular analysis of GANAB null cells show that mutations to GANAB cause ADPKD/ADPLD, that loss/reduction of GIIα associated with maturation and localization defects of PC1 and PC2, and that the identified mutations cannot rescue the PC1 localization defect.
The renal phenotype associated with GANAB mutation is consistently mild without renal insufficiency and any kidney enlargement due to a few large cysts. The GANAB phenotype is more similar to PKD2 than PKD1, but apparently even milder 58 . In one case there was more severe PKD (M656; II-3), and here an undetermined cystogenic influence from the mother may be significant. Applying imaging diagnostic criteria developed in PKD1 and PKD2 families 54; 55 may be unreliable in GANAB families even with a largely renal phenotype given the disease mildness and the variability within families. The significance of the vascular disease, noted in families M641, PK20017 and M472 is presently unclear. Only in M641 do the definitely affected sisters have ICA, with the vascular phenotypes in three other individuals in these families not proven to be GANAB mutation linked.
The liver disease is variable, ranging from no cysts to severe PLD requiring surgical intervention. The highly variable PLD phenotype is characteristic of ADPKD and ADPLD, with no data supporting allelic effects, although some evidence of familial clustering of severe PLD suggesting that genetic modifiers play a significant role 26; 47 . It is interesting that GANAB mutation was identified as the cause of the disease in two of the seven ADPLD-like pedigrees studied, suggesting that the mutation detection rate may be higher in ADPLD families. Although there may be ascertainment bias since ADPKD was the diagnosis in the vast majority of screened families, the overall phenotype appears to involve more renal disease than described in PRKCSH 59 . , and we demonstrate a lack of global, surface glycoprotein deficiencies in GANAB -/-cells, which suggests that endomannosidase activity and other chaperones and folding-assisting proteins can generally compensate for this loss, at least in non-stress conditions. The complexity due to protein size and extensive N-linked glycosylation may underlie the critical dependence of PC1 on GII and the calnexin/calreticulin cycle to achieve native folding. At this stage it is unclear if the enrichment of PLD associated with GII deficiency indicates that the liver is particularly vulnerable to reduction of this enzyme. The defect we observed in GANAB -/-cells is complete disruption of PC1 maturation, increasing ER accumulation of cleaved PC1 with only a marginal effect on GPS-cleavage, in contrast to that described for SEC63 deficiency 16; 62; 64; 65 . In RCTE cells, GANAB heterozygosity was associated with a ~50% reduction of PC1-NTR, a level predisposing to cyst development in association with stochastic, injury and/or somatic events 13; 16; 66; 67 . However, further study is required to fully understand quantitatively how PC1 maturation is influenced by GII dosage, studies that may lead to novel insights into a therapeutic role for cellular and molecular chaperones in ADPKD.
SUPPLEMENTAL DATA Supplemental data includes one table and five figures. 
